Second Genome, Inc., a San Francisco, CA-based developer of a high-throughput platform for rapid and accurate microbiome signature identification and validation, has closed a $5m Series A financing.
The round was co-led by new backer Advanced Technology Ventures (ATV) and Morgenthaler Ventures, with participation from existing shareholders Wavepoint Ventures, Seraph Group, and individual investors.
The company intends to use the funds to further develop its microbiome‐based personalized medicine solutions for gastrointestinal diseases and disorders.
Founded in 2009 as PhyloTech, Inc., and led by Peter DiLaura, President and CEO, and Dr. Corey Goodman, co‐founder and Chairman of the Board of Directors, Second Genome is leveraging its Microbiome Signature Discovery Platform to pursue microbiome-based personalized medicine in gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, antibiotic associated diarrhea, and necrotizing enterocolitis.
The company is now partnering with academic researchers and manufacturers of novel and existing therapies for gastrointestinal diseases, including developers of probiotic, nutraceutical, and pharmaceutical products, to conduct research on the impact of these therapies on the gut microbiome and to develop signatures for improved response.
In conjunction with the funding, Mike Carusi of ATV and Jason Lettmann of Morgenthaler, have joined Second Genome’s Board of Directors. Existing members already include:
– Dr. Corey Goodman;
– Dr. Matt Winkler, CEO of molecular diagnostics company Asuragen;
– Peter Gardner, Managing Director of Wavepoint Ventures; and
– Peter DiLaura.